Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

European Heart Journal

Volumn 24, Issue 8, 2003, Pages 729-741

  Knopp, R H ^a   Gitter, H ^b   Truitt, T ^c   Bays, H ^d   Manion, C V ^e   Lipka, L J ^f   LeBeaut, A P ^f   Suresh, R ^f   Yang, B ^f   Veltri, E P ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Jersey Research Foundation Inc   (United States)

^c Health Advance Institute   (United States)

^d LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^e OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Efficacy; Ezetimibe; Hyperchotesterotaemia; Safety; Selective cholesterol absorption inhibitor

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VITAMIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; HYDROCORTISONE RELEASE; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPID SOLUBILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; COSYNTROPIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TRIGLYCERIDES; VITAMINS;

EID: 0037395141     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)00807-2     Document Type: Article

References (22)

1. van Heek M, France CF, Compton DS et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283:157-63.
2. van Heek M, Farley C, Compton DS et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748-54.
3. van Heek M, Farley C, Compton D et al. The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically. [Abstract]. Atherosclerosis 2000;151: 155.
4. Zhu Y, Statkevich P, Kosoglou T et al. The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor. [Abstract]. AAPS PharmSci 1999;1:S-24. [AAPS Annual Meeting Supplement. Available at http://www.aapspharmaceutica.com/scientificjournals/pharmsci/am_ abstracts/1999/1623.htm].
5. Bays HE, Moore PB, Drehobl MA et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209-30.
6. Zhu Y, Statkevich P, Kosoglou T et al. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo. [Abstract]. Clin Pharmacol Ther 2000;67:152.
7. Kosoglou T, Statkevich P, Bauer KS et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of digoxin. AAPS PharmSci 2001;3(3).
8. Statkevich P, Reyderman L, Kosoglou T et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide. [Abstract]. Clin Pharmacol Ther 2001;69:P67.
9. Keung ACF, Kosoglou T, Statkevich P et al. Ezetimibe does not affect the pharmacokinetics of oral contraceptives. [Abstract]. Clin Pharmacol Ther 2001;69:P5.
10. Bauer KS, Kosoglou T, Statkevich P et al. Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin. [Abstract]. Clin Pharmacol Ther 2001;69:P5.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
12. New York Heart Association. Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis. 6th ed. Boston: Little Brown, 1964. 114pp.
13. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
14. Harris WS, Held SJ, Dujovne CA. Comparison of two scoring systems used to monitor diets in outpatient clinical trials. J Cardiovasc Risk 1995;2:359-65.
15. Stein E. Results of phase 1/11 clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J 2001;3(Suppl E):E11-6.
16. Dujovne CA, Ettinger MP, McNeer JF et al. Ezetimibe, a selective cholesterol absorption inhibitor, improves plasma lipids in hypercholesterolemic patients. Circulation 2001;104(Suppl):II-176.
17. Data on file. Schering-Plough Research Institute. New Jersey: Kenilworth; 2002.
18. Davidson MH, Dillon MA, Gordon B et al. Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900.
19. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251;365-74.
20. Probstfield JL, Statland BE, Gorman L et al. Alterations in human serum alkaline phosphatase and its isoenzymes by hypolipidemic agents: colestipol and clofibrate. Metabolism 1983;32:818-21.
21. Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol 2000;85(12A):15E-9E.
22. van Heek M, Farley C, Compton DS et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;134:409-17.